Appointment of Chief Business Officer
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division.
- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division.
- He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development.
- Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
“As Chief Business Officer, Simon will work closely with the senior management team and lead commercial strategy and business development activities at this exciting period in the Company’s development as compelling clinical data emerges from the AVA6000 phase 1 trial. - Since then, Simon has worked as a consultant providing expert commercial and business development resources to a wide range of biopharmaceutical companies.